It's the second attempt for the rare disease company, which initially announced plans to merge with Candid Therapeutics ...

Ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study that’s seen as an ...

Highly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically ...

Called mezigdomide, the drug is one of two protein-degrading medicines Bristol Myers hopes to soon position as successors to its lucrative Revlimid franchise.

Study results accrued so far are giving Merck greater conviction that the therapy, licensed from a China-based biotech, was worth placing into a sprawling Phase 3 program.

Involving up to 12 antibody drugs, the alliance is the latest broad partnership between Chinese biotech and a multinational pharmaceutical company.

A twice-spurned therapy that’s been seen as one of the FDA’s more controversial recent rejections is getting a new chance ...

David Chang will leave his post after an eight-year run at the cell therapy maker. Elsewhere, a next-generation blood disease drug stumbled and an acquisition yielded an FDA approval for AbbVie.

An RNA-based shot developed by GSK and Ionis Pharmaceuticals helped wipe out hepatitis B in about a fifth of the patients who received it in a pair of clinical trials, according to study results ...

CVS’s decision removes a key advantage Novo had in the GLP-1 marketing war with Lilly. When CVS and Novo announced their deal to give Wegovy preferred status last year, Lilly shares tumbled. “Today’s ...

Formerly known as Verge Genomics, the new Verge Labs will help pharma and biotech partners match potential brain drugs to ...

The company made the announcement after a new round of research results bolstered the case for the experimental medicine, ...